Research Article
The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug
Table 9
Market shares for each therapeutic alternative.
| | Product | 2010 | 2011 | 2012 | 2013 |
| | Denosumab | 0.0% | 2.3% | 5.2% | 8.0% | | Fosamax | 9.7% | 8.6% | 8.2% | 7.7% | | Fosavance | 15.9% | 15.4% | 14.2% | 13.7% | |
Generic alendronate | 27.7% | 27.3% | 27.4% | 27.0% | | Actonel | 24.3% | 24.6% | 24.4% | 24.3% | | Aclasta | 0.3% | 0.4% | 0.4% | 0.4% | | Bonviva oral | 9.3% | 9.0% | 8.3% | 7.9% | | Evista | 1.7% | 1.7% | 1.7% | 1.7% | | Protelos | 9.8% | 9.3% | 8.9% | 8.1% | | Miacalcic | 0.2% | 0.2% | 0.1% | 0.1% | | Teriparatide | 0.9% | 0.9% | 0.9% | 0.9% | | PTH | 0.2% | 0.2% | 0.2% | 0.2% |
| | Total | 100% | 100% | 100% | 100% |
|
|
